Biosimilars | Emerging Biosimilars | Immunology | Inflectra | Wave 1 | US | 2017
Biosimilars│Emerging Biosimilars│Inflectra │U.S. Wave 1 is the first installment of a three-wave, syndicated report series, tracking physician perception and uptake of Pfizer/Celltrion’s Inflectra (biosimilar infliximab [infliximab-dyyb]) in the United States. The series is based on data collected at one, six, and twelve months’ postcommercial launch of Inflectra, with U.S.-based rheumatologists, gastroenterologists, and dermatologists. Along with awareness, familiarity, and perception of biosimilars in general, and Inflectra specifically, the research also explores physicians’ trial, adoption, and usage of Inflectra, including anticipated future trends and impact of its uptake on other immune biologics. Promotional efforts by Johnson & Johnson/Janssen and Pfizer are explored, as well as prescriber and nonprescriber profiles, and benchmarking comparisons against other available biosimilars.
Questions Answered in This Report:
- Are U.S. physicians aware of Inflectra and its clinical development?
- What are the drivers to prescribing Inflectra? What is the current level of Inflectra use, and how is that changing over time?
- How has experience with Inflectra changed physicians’ opinion toward biosimilars?
- Have physicians experienced pressure to prescribe Inflectra? In which settings/patients?
- What promotional messages are sales representatives employing for Inflectra and Remicade?
- How does initial formulary placement of Inflectra compare with other TNF-alpha inhibitors, and does this change over time?
Scope:
- Markets covered: United States
- Primary research: Survey of 91 U.S. rheumatologists, gastroenterologists, and dermatologists
Key Companies Mentioned:
- Amgen
- AbbVie
- Celltrion
- Johnson & Johnson/Janssen
- Pfizer
Key Drugs Mentioned:
- Remicade (infliximab)
- Inflectra (infliximab-dyyb)
- Enbrel (etanercept)
- Humira (adalimumab)
